Adhir Sinha said medicines costing about ₹2,500 in India would have cost nearly ₹42,000 in the US before a 50% insurance discount.
The couple paid US$283 (about ₹23,000) for a doctor's consultation and waited nearly 12 days to obtain the prescribed medicines.
The viral X post has reignited discussion on US healthcare costs, prescription drug pricing, medical insurance, and healthcare affordability compared with India.
An Indian senior citizen's account of seeking medical treatment in Seattle has gone viral after Adhir Sinha shared on X on July 5 that medicines costing about ₹2,500 in India would have cost nearly ₹42,000 in the US before insurance discounts. He also said the couple later received a US$283 (around ₹23,000) bill for a doctor's consultation, prompting renewed discussion on US healthcare costs, prescription drug prices, and healthcare affordability.
According to Sinha, he and his wife had been staying in Seattle for two months when they ran out of medicines prescribed in India for her respiratory illness. After consulting a physician and waiting several days for the prescription to be filled, he was surprised to find the medicines were manufactured by Cipla and labelled "Made in India." Reflecting on the experience, Sinha wrote, "This means medicines costing just ₹2,500 in India cost a staggering ₹42,000 in the US."
Sinha wrote that his daughter initially tried to book an appointment with a pulmonologist in Seattle after his wife ran out of medicines prescribed in India for a respiratory illness. However, they first had to consult a general physician and were offered a video consultation a week later.
"We spoke to the doctor on the phone for about 10 minutes. He said he understood the issue and prescribed appropriate medicines," Sinha wrote. The prescribed medicines were unavailable immediately and reached the pharmacy five days later. He said he was surprised to find they had been manufactured by Cipla and carried a "Made in India" label.
Despite receiving a 50% discount through US medical insurance, the couple still paid about ₹21,000 for the medicines.
A week later, the family received a US$283 (around ₹23,000) bill for the doctor's consultation. Overall, Sinha said the process took 12 days to obtain medicines that are "readily available at any pharmacy in India," taking the total medical expense to more than ₹65,000.
Sinha's post has reignited discussion about US healthcare costs, where patients may be billed separately for consultations, diagnostic tests, and prescription medicines. In the US, physician consultations, medicines, and diagnostic tests are commonly billed separately, unlike many healthcare systems where some services may be bundled depending on the care setting and insurance arrangement. Even people with health insurance can face high out-of-pocket costs depending on their policy and the medicines prescribed.
Prescription drug prices in the United States are often higher because manufacturers generally set list prices, while insurance coverage, negotiated rebates, and patient cost-sharing vary across health plans. In contrast, India has a large generic pharmaceutical industry and regulates the prices of several essential medicines, helping keep many commonly used drugs more affordable.
At the same time, several social media users noted that comparing the two healthcare systems is not straightforward, arguing that the US offers broader access to specialized treatment, advanced medical technology, and complex care, factors that can contribute to higher healthcare spending.
Reflecting on the experience, Sinha said it made him value the ease of accessing healthcare in India, where specialist consultations, prescription medicines, diagnostic tests, neighborhood pharmacies, and digital payments are often available more quickly and at lower cost. He wrote, "Consider yourselves to be fortunate to be living in India during your retirement years."
Beyond healthcare, Sinha also pointed to affordable mobile data, doorstep grocery delivery, domestic help, and strong neighborhood support as everyday conveniences that he believes are difficult or more expensive to access in many other countries. Concluding his post, he wrote, "India is not merely a country; it is a wonderful world filled with conveniences at every turn."
Also see: The Future of India’s Pharmaceutical Industry: Growth, Risks & Global Opportunities
The viral post sparked debate, with many highlighting the high cost of routine healthcare in the US, while others emphasized that comparisons with India must consider differences in insurance systems, funding, and access to advanced medical care.
In his post, Adhir Sinha reflected on the broader experience of living abroad, writing, "We often look abroad in search of a 'good life.' But if we pause to think... certain everyday conveniences—unavailable even to billionaires in London or New York—are easily accessible to the middle class in India."
(Rh/TP/MSM)